Mission Statement, Vision, & Core Values (2026) of Siegfried Holding AG.

With a legacy stretching back 150 years, Siegfried Holding AG has evolved into a global life‑sciences partner that scales cutting‑edge innovations into manufacturable medicines, serving customers that include numerous Fortune 500 pharma firms; operating across 7 sites in Switzerland, Germany, Spain, France, Malta, the USA and China, the company combines API and drug‑product expertise with heavy R&D investment, a mission to 'take the precious innovations of its pharmaceutical customers to industrial scale, with mastery of science and technology, and manufacture safe drugs for patients worldwide,' and a vision to be 'the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space,' all grounded in core values of Excellence, Passion, Integrity, Quality and Sustainability-explore how these pillars translate into concrete operational moves, sustainability targets and customer‑centric strategies that define Siegfried's competitive network.

Siegfried Holding AG (0QQO.L) - Intro

• Core businesses: API development & manufacturing, drug product development & contract manufacturing (CDMO).
• Geographic footprint: Switzerland, Germany, Spain, France, Malta, USA, China - enabling global supply continuity and regulatory coverage (EMA, FDA, Swissmedic, MFDS, NMPA assessments and approvals across sites).
• Customer base: multinational pharma, biotech innovators, and generics firms; strong long-term partnerships and multi-year supply contracts.

• Mission: deliver reliable, compliant and innovative chemistry and drug-product solutions that enable customers to bring medicines to patients safely and at scale.
• Vision: be the preferred fully integrated partner for complex APIs and finished-dose forms, driven by operational excellence, regulatory reliability and targeted R&D.
• Strategic priorities: expand CDMO capabilities, invest in complex API technologies (e.g., highly potent APIs, continuous manufacturing), strengthen capacity in high-demand therapy areas, and deepen sustainability integration across operations.

• Quality systems: multi-site GMP certification and frequent regulatory inspections with corrective action integration to maintain supply reliability.
• Innovation investments: targeted capital and technical spend to scale continuous processing, containment technology for HPAPIs, and analytical development to reduce time‑to‑market for customers.
• Platform growth: expanding finished-dose capabilities (blistering, sterile and non-sterile dosage forms) to capture higher-value CDMO contracts.

• Environmental focus: initiatives to reduce energy intensity, lower direct CO2 emissions, improve wastewater treatment and optimize solvent recovery in API processes.
• Social & governance: workforce safety programs, employee development, and governance frameworks aligning with international compliance and supplier responsibility standards.

• Supply continuity: global site diversification and multi-source manufacturing strategies to mitigate regional disruptions and regulatory risk.
• Service model: integrated development-to-commercialization offerings that shorten customer timelines and consolidate supplier relationships.

Siegfried Holding AG (0QQO.L) - Overview

• Industrial-scale translation: focus on scaling lab innovations to multi-tonne API and high-volume finished-dosage manufacturing while preserving quality and regulatory compliance.
• Mastery of science & technology: continuous investment in process development, analytical capabilities, and advanced manufacturing technologies (e.g., high-potency containment, continuous processing).
• Patient-first safety orientation: formalized quality systems, regulatory track record and pharmacovigilance integration to ensure manufactured medicines meet safety and efficacy standards.
• Strategic capital investment: targeted investments in new plants, capacity expansions and R&D centers to support long-term customer programs and biosafety/high-potency demand.

• Capacity investments: multi-year CAPEX programs aimed at expanding high-potency and sterile manufacturing capacity to capture growing oncology and specialty API demand.
• Quality & regulatory outcomes: sustained GMP compliance across sites with regulatory inspections and approval track records supporting market access for clients' products.
• Technology adoption: deployment of process intensification, advanced analytics and containment systems to reduce cycle times and manage OEL (occupational exposure limit) risks.
• Customer partnership model: long-term supply agreements, tech-transfer teams and integrated development services to de-risk commercialization for clients.

• Quality culture: documented quality management systems, training programs and cross-site audit frameworks to ensure consistent product safety.
• Sustainability & compliance: environmental, health & safety (EHS) investments and reporting aligned with regulatory expectations and customer sustainability requirements.
• Talent and knowledge retention: technical centers of excellence, cross-site mobility and strategic hiring to preserve institutional know-how essential for scaling complex processes.

• Investor communications emphasize the mission-driven capital investments underpinning future revenue visibility and margin improvement.
• Operational KPIs (utilization, on-time deliveries, regulatory status) are used to demonstrate the mission's impact on customer trust and long-term contracts.
• For deeper investor context: Exploring Siegfried Holding AG Investor Profile: Who's Buying and Why?

Siegfried Holding AG (0QQO.L) - Mission Statement

• Trust and long‑term partnerships: prioritize reliability, regulatory compliance and transparency in supplier-customer relationships.
• End‑to‑end capability: combine development, API and finished‑dosage manufacturing to shorten timelines and reduce transfer risk for customers.
• Network competitiveness: leverage geographically diversified sites to manage supply security, capacity flexibility and cost efficiency.
• People and teamwork: invest in skilled personnel, cross‑site collaboration and continuous improvement to maintain operational excellence.

• Network expansion and modernization: targeted site upgrades and selective capacity additions to meet biologics and small‑molecule demand.
• Quality & compliance focus: sustained investment in regulatory inspections, GMP capabilities and digital quality systems to maintain trust.
• Service integration: packaging, formulation, API and analytical services bundled to lower customer complexity and improve time‑to‑market.
• M&A and partnerships: inorganic moves to fill capability gaps, expand therapeutic or geographic coverage and accelerate access to new technologies.

• On‑time delivery rate and customer satisfaction/NPS.
• Regulatory inspection outcomes and product release timelines.
• Utilization rates across key production lines and time‑to‑first‑commercial batches.
• Revenue growth and margin trajectory in CDMO services vs. industry benchmarks.

Siegfried Holding AG (0QQO.L) - Vision Statement

• Excellence - Continuous operational improvement, process optimization, and targeted investments in capacity and technology to raise productivity and compliance.
• Passion - A workforce-driven focus on innovation and customer intimacy that shortens time-to-market and improves service reliability for pharma partners.
• Integrity - Transparent governance, strong compliance culture, and ethical conduct across R&D, manufacturing, supply chain and commercial interactions.
• Quality - Rigorous quality systems and validation practices to ensure products meet regulatory standards and patient-safety requirements "right first time."
• Sustainability - Embedding environmental and social metrics into strategy: emission reductions, waste management, energy efficiency and community engagement.

• Excellence - KPI-driven manufacturing: target batch-release lead-time reductions and continuous improvement programs that contributed to adjusted EBITDA margin improvements in recent years.
• Passion - Employee engagement initiatives and training programs; internal metrics track innovation pipeline throughput and customer NPS scores.
• Integrity - Robust compliance metrics: regulatory inspection closure rates, audit findings reduced year-over-year, and transparent board-level reporting.
• Quality - Low deviation rates, validated processes across multiple cGMP sites, and investment in digital quality-management systems.
• Sustainability - Energy-efficiency projects, waste-water treatment investments, and supplier sustainability assessments to support scope‑1 and scope‑2 emission reductions.

• Financial: revenue growth, adjusted EBITDA margin, free cash flow conversion and return on capital employed (ROCE).
• Quality & Compliance: batch release timeliness, inspection findings closed within target, and customer complaint rates.
• People: employee retention, training hours per FTE and safety incident rates (TRIR/LTIR).
• Sustainability: CO2 emissions (scope 1 & 2), energy consumption per kg product, and waste diverted from landfill.